Each UROQID-Acid® No.2 tablet contains methenamine mandelate 500 mg and sodium acid phosphate, monohydrate 500 mg.
For the suppression or elimination of bacteriuria associated with chronic and recurrent infections of the urinary tract, including pyelitis, pyelonephritis, cystitis, and infected residual urine accompanying neurogenic bladder. When used as recommended, UROQID-Acid® No.2 is particularly suitable for long-term therapy because of its relative safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond because of the nonspecific effect of formaldehyde formed in an acid urine.
Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine can prevent recurrence of bacteriuria in patients with chronic pyelonephritis.
Therapeutic Use Rationale: Helps to sterilize the urine and, in some situations in which underlying pathologic conditions prevent sterilization by any means, can help to suppress bacteriuria. As part of the overall management of the urinary tract infection, a thorough diagnostic evaluation should accompany the use of this product.